Efficacy and safety of imatinib on top of BFM-like chemotherapy in pediatric patients with Ph+/BCR-ABL+ acute lymphoblastic leukemia (Ph+ALL). the EsPhALL study

Research output: Contribution to journalPublished meeting abstract


Background. Philadelphia chromosome positive (Ph+) ALL accounts for 3-5% of pediatric ALL. An international survey on 640 children diagnosed between 1995 and 2005 and treated with chemotherapy and stem cell transplantation (SCT) without the use of tyrosin kinase inhibitors (TKI) recently reported an overall 7-year event free survival (EFS) and overall survival (OS) of 31.2% and 44.2%, respectively. In those years, only limited experience was accumulated on the use of Imatinib (IM) for children with Ph+ leukemia. The EsPhALL study was designed as an intergroup, open-label, randomized Phase II/III study, within the I-BFM-SG network, to assess the safety and efficacy of IM in association with chemotherapy. Ten national study groups participated in the study: AIEOP, BFM-G/CH, COALL, FRALLE, NOPHO, MRC, DCOG, CPH, PINDA and HONG KONG. Methods. Patients 1 to 18 years of age diagnosed with Ph+ ALL were eligible to the study. After the induction phase according to national treatment protocol, patients were classified as Good Risk (GR) or Poor Risk (PR) according to their response to treatment. GR patients were those who achieved both the early response (i.e. blast cell count


  • Andrea Biondi
  • Martin Schrappe
  • Paola De Lorenzo
  • Anders Castor
  • Giovanna Lucchini
  • Virginie Gandemer
  • Rob Pieters
  • Jan Stary
  • Gabriele Escherich
  • Myriam Campbell
  • Ci Kong-Li
  • Ajay J. Vora
  • Gudmar Lonnerholm
  • Maurizio Arico
  • Jochen Harbott
  • Vaskar Saha
  • Maria Grazia Valsecchi
External organisations
  • University of Milano-Bicocca
  • University Medical Center Schleswig-Holstein Campus Kiel
  • Erasmus University Rotterdam
  • Charles University in Prague
  • University Medical Center Hamburg-Eppendorf
  • University of Chile
  • Sheffield Children's Hospital
  • Uppsala University Hospital
  • Children's Cancer Group
  • Skåne University Hospital
  • University of Florence
  • Rennes University Hospital
  • University of Rennes I
  • Justus Liebig University Giessen
Research areas and keywords


  • imatinib, tyrosine, phosphotransferase inhibitor, prednisone, methotrexate, hemoglobin, human, pH, patient, acute lymphoblastic leukemia, society, chemotherapy, hematology, safety, arm, risk, donor, remission, child, bone marrow, single drug dose, stem cell transplantation, randomization, Philadelphia chromosome positive cell, blood, thrombocyte, cell count, granulocyte, leukocyte, blast cell, intrathecal drug administration, leukemia, relapse, overall survival, log rank test, disease free survival, death, allele, genotype, event free survival, infection
Original languageEnglish
Article numberAbstract 873
Issue number21
Publication statusPublished - 2011 Nov 18
Publication categoryResearch
Externally publishedYes
Event53rd Annual Meeting of the American Society of Hematology - San Diego, United States
Duration: 2011 Dec 102011 Dec 13